Analysis Moderna’s Melanoma Win Is Clinically Real. Citi’s Sell Call Says the Economics Aren’t.
Moderna’s latest melanoma data have done nothing to settle the argument that matters most for the stock: whether a personalized cancer therapy can earn its keep once the manufacturing bill...